Laura Gramantieri

List of Publications by Citations

101 papers	7,112 citations	39 h-index	83 g-index
106 ext. papers	7,794 ext. citations	6.4 avg, IF	5.16 L-index

#	Paper	IF	Citations
101	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. *Cancer Research*, **2007**, 67, 6092-9	10.1	695
100	Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. *Cancer Cell*, **2007**, 12, 215-29	24.3	599
99	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. *Oncogene*, **2008**, 27, 5651-61	9.2	545
98	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. *Gut*, **2001**, 48, 251-9	19.2	477
97	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. *Cancer Research*, **2010**, 70, 5184-93	10.1	347
96	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. *Cancer Research*, **2009**, 69, 5761-7	10.1	346
95	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. *Clinical Cancer Research*, **2009**, 15, 5073-81	12.9	267
94	Oncogenic role of miR-483-3p at the IGF2/483 locus. *Cancer Research*, **2010**, 70, 3140-9	10.1	239
93	What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. *Journal of Hepatology* , **1997**, 27, 979-85	13.4	215
92	MicroRNA involvement in hepatocellular carcinoma. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 2189-204	5.6	212
91	In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. *Journal of Pathology*, **2012**, 227, 275-85	9.4	155
90	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. *Hepatology*, **2012**, 56, 1025-33	11.2	132
89	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. *Hepatology*, **1999**, 30, 58-64	11.2	126
88	MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. *Cell Death and Differentiation*, **2015**, 22, 46-57	12.7	114
87	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. *Clinical Cancer Research*, **2017**, 23, 3953-3965	12.9	105
86	Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. *Liver International*, **2014**, 34, e302-7	7.9	98
85	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. *PLoS ONE*, **2015**, 10, e0141448	3.7	94

84	Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. *Cancer Research*, **2004**, 64, 8156-9	10.1	89
83	Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. *Liver International*, **2007**, 27, 997-1007	7.9	88
82	Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. *Journal of Hepatology*, **2009**, 50, 969-79	13.4	81
81	Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. *Free Radical Research*, **2002**, 36, 939-48	4	80
80	microRNA involvement in hepatocellular carcinoma. *Anti-Cancer Agents in Medicinal Chemistry*, **2011**, 11, 500-21	2.2	78
79	Hepatocellular carcinoma: epidemiology and clinical aspects. *Molecular Aspects of Medicine*, **2008**, 29, 130-43	16.7	78
78	Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 5445-9	11.5	74
77	Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. *Oncotarget*, **2016**, 7, 32375-93	3.3	60
76	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. *Molecular Therapy - Nucleic Acids*, **2018**, 11, 485-493	10.7	59
75	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. *Oncotarget*, **2018**, 9, 15350-15364	3.3	59
74	Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. *Ultrasound in Medicine and Biology*, **2001**, 27, 893-9	3.5	54
73	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. *Ultrasound in Medicine and Biology*, **1997**, 23, 675-82	3.5	49
72	Loss of methylation at chromosome 11p15.5 is common in human adult tumors. *Oncogene*, **2002**, 21, 2564-72	9.2	49
71	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. *Cell Death and Disease*, **2018**, 9, 4	9.8	48
70	The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1 activity by changing miR expression patterns in human cancer cells. *Molecular Cancer Therapeutics*, **2014**, 13, 239-48	6.1	48
69	CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma. *American Journal of Pathology*, **2012**, 181, 413-22	5.8	46
68	Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. *Hepatology*, **2015**, 61, 249-59	11.2	45
67	Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. *PLoS ONE*, **2013**, 8, e73964	3.7	45

66	Mutated beta-catenin evades a microRNA-dependent regulatory loop. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 4840-5	11.5	43
65	Role of microRNAs in hepatocellular carcinoma: a clinical perspective. *OncoTargets and Therapy*, **2013**, 6, 1167-78	4.4	42
64	Serum xanthine oxidase in human liver disease. *American Journal of Gastroenterology*, **2001**, 96, 1194-9	0.7	40
63	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. *Oncotarget*, **2013**, 4, 1618-31	3.3	40
62	In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. *Journal of Hepatology*, **2003**, 39, 997-1003	13.4	37
61	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. *Oncotarget*, **2014**, 5, 10607-20	3.3	37
60	p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. *Molecular Cancer Research*, **2014**, 12, 203-16	6.6	36
59	Assessment of vascular patterns of small liver mass lesions: value and limitation of the different Doppler ultrasound modalities. *American Journal of Gastroenterology*, **2000**, 95, 3537-46	0.7	35
58	Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. *Oncogene*, **2019**, 38, 7035-7045	9.2	34
57	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. *Hepatology*, **2000**, 31, 349-57	11.2	33
56	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 31361-71	3.3	33
55	Multigene Methylation Analysis of Gastrointestinal Tumors. *Molecular Diagnosis and Therapy*, **2003**, 7, 201-207		32
54	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. *Frontiers in Genetics*, **2013**, 4, 64	4.5	31
53	LncRNAs as novel players in hepatocellular carcinoma recurrence. *Oncotarget*, **2018**, 9, 35085-35099	3.3	31
52	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. *American Journal of Gastroenterology*, **1998**, 93, 1925-30	0.7	30
51	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. *European Journal of Medicinal Chemistry*, **2012**, 48, 391-401	6.8	28
50	Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. *European Journal of Gastroenterology and Hepatology*, **1997**, 9, 799-804	2.2	28
49	Notch3 intracellular domain accumulates in HepG2 cell line. *Anticancer Research*, **2006**, 26, 2123-7	2.3	28

48	MiR-30e-3p Influences Tumor Phenotype through / Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. *Cancer Research*, **2020**, 80, 1720-1734	10.1	27
47	Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. *International Journal of Molecular Sciences*, **2016**, 18,	6.3	27
46	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. *Journal of Clinical Medicine*, **2019**, 8,	5.1	26
45	GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation. *Human Pathology*, **2005**, 36, 1154-62	3.7	25
44	Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. *Clinical and Experimental Immunology*, **1999**, 115, 515-20	6.2	25
43	c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. *Journal of Hepatocellular Carcinoma*, **2015**, 2, 29-38	5.3	23
42	MicroRNA response to environmental mutagens in liver. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2011**, 717, 67-76	3.3	22
41	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	22
40	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 39609-39626	3.3	21
39	The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. *Journal of Hepatology*, **2016**, 64, 891-8	13.4	20
38	From liver cirrhosis to HCC. *Internal and Emergency Medicine*, **2011**, 6 Suppl 1, 93-8	3.7	20
37	Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA). *Clinica Chimica Acta*, **1999**, 281, 147-58	6.2	19
36	Diagnostic and prognostic value of DNA ploidy and cell nuclearity in ultrasound-guided liver biopsies. *Cancer*, **1994**, 74, 1713-9	6.4	19
35	Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. *Journal of Hepatology*, **2020**, 72, 1159-1169	13.4	17
34	Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1319-26	5.9	17
33	Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. *Molecular Diagnosis and Therapy*, **2003**, 7, 201-7		17
32	In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. *Journal of Hepatology*, **1996**, 24, 60-5	13.4	17
31	Role of SIRT-3, p-mTOR and HIF-1 In Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	16

30	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. *Acta Histochemica*, **2018**, 120, 95-102	2	16
29	Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation. *Laboratory Investigation*, **2008**, 88, 995-1007	5.9	15
28	MicroRNAs in Animal Models of HCC. *Cancers*, **2019**, 11,	6.6	14
27	Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. *Journal of Medical Virology*, **2000**, 62, 25-8	19.7	13
26	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. *Journal of Gastroenterology and Hepatology (Australia)*, **1996**, 11, 1115-20	4	13
25	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. *Digestive Diseases and Sciences*, **2017**, 62, 2397-2407	4	12
24	Liver metastases from rectal carcinoma: disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. *Journal of Clinical Ultrasound*, **2003**, 31, 387-91	1	12
23	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. *Scientific Reports*, **2017**, 7, 44685	4.9	10
22	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. *Clinical Cancer Research*, **2020**, 26, 4485-4493	12.9	9
21	Possible mechanisms for changes of intrasplenic arterial impedance indices in portal hypertension. *Hepatology*, **1997**, 26, 513-4	11.2	9
20	Duplex Doppler findings in splenic arteriovenous fistula. *Journal of Clinical Ultrasound*, **1998**, 26, 103-5	1	9
19	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 369-385	5.3	9
18	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. *Molecular Therapy - Nucleic Acids*, **2019**, 14, 239-250	10.7	9
17	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. *Digestive Diseases and Sciences*, **1996**, 41, 800-8	4	8
16	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. *Targeted Oncology*, **2020**, 15, 773-785	5	8
15	Alteration of DNA ploidy and cell nuclearity in human hepatocellular carcinoma associated with HBV infection. *Journal of Hepatology*, **1996**, 25, 848-53	13.4	7
14	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 741-757	5.3	7
13	Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis. *Alimentary Pharmacology and Therapeutics*, **1998**, 12, 475-81	6.1	6

12	Animal Models of Hepatocellular Carcinoma Prevention. *Cancers*, **2019**, 11,	6.6	6
11	Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. *Oncotarget*, **2018**, 9, 17895-17905	3.3	5
10	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. *Cancers*, **2020**, 12,	6.6	5
9	Brivanib in combination with Notch3 silencing shows potent activity in tumour models. *British Journal of Cancer*, **2019**, 120, 601-611	8.7	5
8	Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate. *Digestive Diseases and Sciences*, **2000**, 45, 306-11	4	3
7	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. *Cells*, **2021**, 10,	7.9	3
6	Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. *Digestive and Liver Disease*, **2004**, 36, 594-602	3.3	2
5	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. *Cancers*, **2021**, 13,	6.6	2
4	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. *Gastrointestinal Cancer: Targets and Therapy*, **2015**, 89		
3	A case of extracranial vertebral artery dissection with spontaneous recovery Diagnosis and follow-up by duplex and color Doppler. *European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology*, **1997**, 6, 197-201		
2	Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. *OncoTargets and Therapy*, **2021**, 14, 4305-4308	4.4	
1	Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma **2022**, 301-315		